28 papers · ranked by Valyu relevance
Mesude Bicak, Cansu Cimen Bozkus, Nina Bhardwaj
In the late 1800s, observations that bacterial infections could lead to tumor regression and that the immune system could recognize and eliminate precancerous cells, later proved by the identification of lymphocytes in the 1950s, shepherded a new era of cancer immunology and immunotherapy. Subsequently, the discoveries…
Kavita Iyer, Julian Ivanov, Rumiana Tenchov, Krittika Ralhan + 4 more
Rapid and sustained growth in the field of immuno-oncology has resulted in expansion of available scientific literature. Gaining valuable insights and establishing deep and often hidden meaningful connections in such a large body of work is the need of the hour. In this report we summarize our findings from a novel…
Lu Yu, Minghan Sun, Qi Zhang, Qiao Zhou + 1 more
With the goal of harnessing the host’s immune system to provide long-lasting remission and cures for various cancers, the advent of immunotherapy revolutionized the cancer therapy field. Among the current immunotherapeutic strategies, immune checkpoint blockades have greatly improved the overall survival rates in…
Kamran Kaveh, Feng Fu
Immune checkpoint therapy is one of the most promising immunotherapeutic methods that are likely able to give rise to durable treatment response for various cancer types. Despite much progress in the past decade, there are still critical open questions with particular regards to quantifying and predicting the efficacy…
Negar Hosseinkhani, Afshin Derakhshani, Omid Kooshkaki, Mahdi Abdoli Shadbad + 8 more
'Mahdi Abdoli Shadbad' 'Khalil Hajiasgharzadeh' 'Amir Baghbanzadeh' 'Hossein Safarpour' 'Ahad Mokhtarzadeh' 'Oronzo Brunetti' 'Simon C. Yue' 'Nicola Silvestris' 'Behzad Baradaran'] Although the ever-increasing number of cancer patients pose substantial challenges worldwide, finding a treatment with the highest response…
Sneha Vivekanandhan, Deborah Bahr, Ashish Kothari, Mohammed Ali Ashary + 2 more
'Mohammed Ali Ashary' 'Mizba Baksh' 'Emmanuel Gabriel'] Cancer remains a leading cause of death worldwide, placing a significant burden on healthcare systems as well as the global economy. Rare cancers comprise a group of about 200 cancers that individually occur at extremely low frequencies. In the United States (US)…
I-Tsu Chyuan, Ching-Liang Chu, Ping-Ning Hsu, Armand Bensussan
Simple Summary Immune checkpoint inhibitors (ICIs) constitute a paradigm shift in cancer therapy, and it has greatly expanded our knowledge of anticancer immunity and has introduced breakthroughs in cancer therapy. However, despite the promising results in the use of immunotherapy in some cancers, numerous patients do…
Shiu-Jau Chen, Shao-Cheng Wang, Yuan-Chuan Chen, Federico Cappuzzo
Immunotherapy is a novel anti-cancer method which employs a different mechanism to conventional treatment. It has become a significant strategy because it provides a better or an alternative option for cancer patients. Recently, immunotherapy has been increasingly approved for the treatment of cancer; however, it has…
Collin Y. Zheng, Peter Kim
We introduce a set of ordinary differential equations (ODE) that qualitatively reproduces delayed responses observed in immune checkpoint blockade therapy (e.g. anti-CTLA-4 Ipilimumab). This type of immunotherapy has been at the forefront of novel and promising cancer treatments over the past decade and was recognised…
Rashmi P Mohanty, Yuting Pan, Mae M Lewis, Melissa Soto + 3 more
Tumor extracellular matrix (ECM) forms a net negative charged network that interacts with and hinders the transport of molecules partly based on electrostatic interactions. The focus on drug delivery in solid tumors has traditionally been on developing neutral charge coatings to minimize interactions with the ECM for…
Yixuan Wang, Daniel Bergman, Erica Trujillo, Alexander T. Pearson + 2 more
Immunotherapy has dramatically transformed the cancer treatment landscape largely due to the efficacy of immune checkpoint inhibitors (ICIs). Although ICIs have shown promising results for many patients, the low response rates in many cancers highlight the ongoing challenges in cancer treatment. Cytotoxic T lymphocytes…
Izabela Karwacka, Łukasz Obołończyk, Sonia Kaniuka-Jakubowska, Krzysztof Sworczak
'Krzysztof Sworczak'] Adrenocortical carcinoma (ACC) is a rare epithelial neoplasm, with a high tendency for local invasion and distant metastases, with limited treatment options. Surgical treatment is the method of choice. For decades, the mainstay of pharmacological treatment has been the adrenolytic drug mitotane…
Md. Mominur Rahman, Tapan Behl, Md. Rezaul Islam, Md. Noor Alam + 6 more
Immunotherapy, which stimulates the body’s immune system, has received a considerable amount of press in recent years because of its powerful benefits. Cancer immunotherapy has shown long-term results in patients with advanced disease that are not seen with traditional chemotherapy. Immune checkpoint inhibitors…
Yile Wang, Ziyan Kong, Yunqi Zhao, Bing Pei + 7 more
Cancer immunotherapy has made significant advancements over the past few decades, with immune checkpoint and cytokine-based drugs being successfully implemented in clinical settings. Nonetheless, the effective and safe clinical application of these therapies is hindered by critical issues, such as severe toxicity to…
Weizhi Wang, Limin Zhang
Blocking programmed cell death ligand 1 (PD-L1) in tumor cells is an effective therapy strategy to achieve immune system activation for tumor therapy, however only a few patients can benefit from it. Development of synergistic therapy with checkpoint PD-L1 blockade immunotherapy is beneficial to enhance antitumor…
Authors not listed
Immuno-oncology, a rapidly evolving field at the forefront of cancer research, leverages the body’s immune system to fight cancer. In this follow up report, we extend our natural language processing (NLP)-based analysis to pinpoint the context of emergence of the previously identified emerging concepts. To achieve this…
Chenghang Li, Haifeng Zhang, Xiulan Lai, Jinzhi Lei
The tumor-immune system plays a critical role in colorectal cancer progression. Recent preclinical and clinical studies showed that combination therapy with anti-PD-L1 and cancer vaccines improved treatment response. In this study, we developed a multiscale mathematical model of interactions among tumors, immune cells…
Santosh Kumar Paidi, Joel Rodríguez Troncoso, Piyush Raj, Paola Monterroso Díaz + 3 more
'Paola Monterroso Díaz' 'David E. Lee' 'Narasimhan Rajaram' 'Ishan Barman'] Cancer immunotherapy provides durable clinical benefit in only a small fraction of patients, particularly due to a lack of reliable biomarkers for accurate prediction of treatment outcomes and evaluation of response. Here, we demonstrate the…
Haidong Dong
Following antigen stimulation, the net outcomes of a T cell response are shaped by integrated signals from both positive co-stimulatory and negative regulatory molecules. Recently, the blockade of negative regulatory molecules (i.e. immune checkpoint signals) demonstrates promising therapeutic effects in treatment of…
Tibor Bakács, Katalin Kristóf, J.N. Mehrishi, Tamás Szabados + 3 more
'Csaba Kerepesi' 'Enikoe Regoes' 'Gábor Tusnády'] 1Department of Probability, Alfred Renyi Institute of Mathematics, The Hungarian Academy of Sciences, 1053 Budapest, Reáltanoda str. 13-15. Hungary; 2Department of Anesthesiology, Emergency and Intensive Care Medicine, University of Göttingen, Robert-Koch-Str. 40…
Amy K Erbe, Arika S. Feils, Anqi Gao, Sabrina VandenHeuvel + 17 more
Despite advances in treatment, >50% of patients with advanced melanoma are unresponsive to current therapies. Using the B78-D14 melanoma model (GD2^+^/MHC-I^-^/MHC-II^+^), we can cure mice with a regimen that includes radiotherapy (RT) in combination with immunocytokine (IC; anti-GD2 monoclonal antibody linked to IL-2)…
Gilli Galore-Haskel, Efrat Merhavi-Shoham, Mika Shapiro, Roni Bareli + 15 more
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, yet their efficacy remains limited. Therefore, there is a clear need for new anti-tumor agents. HVEM (Herpes Virus Entry Mediator) plays a regulatory role in immunity, making it a promising cancer therapeutic target. We have developed Anti-4CB1…
Guangchuan Wang, Feifei Zhang, Ryan D. Chow, Emily He + 3 more
The hostile tumor microenvironment (TME) is major challenge for cancer immunotherapies. Here, we design and perform TME-targeted in vivo CRISPR activation (CRISPRa) screens to uncover factors that promote anti-tumor immunity, culminating in rationally designed immune gene therapy combinations. Through adeno-associated…
Paula Kroon, Elselien Frijlink, Victoria Iglesias-Guimarais, Andriy Volkov + 5 more
To increase cancer immunotherapy success, PD-1 blockade must be combined with rationally selected treatments. Here, we examined in a poorly immunogenic mouse breast cancer model the potential of antibody-based immunomodulation and conventional anti-cancer treatments to collaborate with anti-PD-1 treatment. One…
Huanyu Shi, Haotian Tang, Yan Li, Danqi Chen + 7 more
Hematopoietic progenitor kinase 1 (HPK1) is a serine/threonine kinase that serves as the negative regulator of multiple immune signaling pathways. Genetic studies using HPK1 knockout and kinase-dead mice suggested that inhibiting HPK1 either alone or in combination with immune checkpoint blockade could be promising…
Authors not listed
Blinatumomab is an FDA-approved bispecific T Cell engager(BiTE) that binds CD3 on T cells and CD19 on B cells, redirecting cytotoxic T cell activity to malignant B cells. Blinatumomab has achieved clinical success in treating B-cell acute lymphoblastic leukemia(B-ALL), however, the structural and functional…
Daniel Y. Yuan, Michelle L. McKeague, Vineet K. Raghu, Robert E. Schoen + 2 more
A single arm trial (NCT007773097) and a double-blind, placebo controlled randomized trial (NCT02134925) were conducted in individuals with a history of advanced colonic adenoma to test the safety and immunogenicity of the MUC1 tumor antigen vaccine and its potential to prevent new adenomas. These were the first two…
Authors not listed
Melanoma is a type of skin cancer originating in the melanocytes and is recognized as one of the most severe and challenging forms of skin cancer to treat. Tyrosinase-related protein 1 (TYRP1) is a crucial protein involved in melanin production and is notably overexpressed in melanoma cells. Recently, TYRP1 has been…